» Articles » PMID: 37637856

Prevention of Uterine Fibroids: Molecular Mechanisms and Potential Clinical Application

Overview
Date 2023 Aug 28
PMID 37637856
Authors
Affiliations
Soon will be listed here.
Abstract

Uterine fibroids (UFs; leiomyoma) are the most common benign neoplastic threat to women worldwide, exacting an immense personal burden on female health and a monetary expense to the healthcare system estimated in the hundreds of billions of dollars every year globally. With no long-term non-invasive treatment option currently available to treat UFs, deeper insights regarding tumor etiology are the key for developing newer therapies. Accordingly, in this review, we discuss new mechanistic paradigm to explain UF tumor development through an exquisite model involving developmental reprogramming of myometrial stem cells due to early life endocrine disruptors exposure, inflammation, fibrosis, DNA damage, and eventually tissue stiffness. Further, we propose to utilize shear wave elastography as a potential screening tool for the early identification of women at risk for developing UFs who can benefit from several simple preventive strategies, including the consumption of natural compounds such as vitamin D and green tea as a safe fertility friendly non-hormonal modality to delay or even arrest or reverse UF progression.

Citing Articles

Multiparametric quantitative magnetic resonance imaging of uterine fibroids for prediction of growth rate-a pilot study.

Medved M, Harmath C, Siblini H, Giurcanu M, Kulkarni K, Hellman K Quant Imaging Med Surg. 2024; 14(7):4362-4375.

PMID: 39022288 PMC: 11250352. DOI: 10.21037/qims-23-1663.


Empowering Strategies for Lifestyle Interventions, Diet Modifications, and Environmental Practices for Uterine Fibroid Prevention; Unveiling the LIFE UP Awareness.

Vafaei S, Alkhrait S, Yang Q, Ali M, Al-Hendy A Nutrients. 2024; 16(6).

PMID: 38542717 PMC: 10975324. DOI: 10.3390/nu16060807.


Evidence-Based Approach for Secondary Prevention of Uterine Fibroids (The ESCAPE Approach).

Vafaei S, Ciebiera M, Omran M, Mousaei Ghasroldasht M, Yang Q, Leake T Int J Mol Sci. 2023; 24(21).

PMID: 37958957 PMC: 10648339. DOI: 10.3390/ijms242115972.


Current and Emerging Treatment Options for Uterine Fibroids.

Ali M, Ciebiera M, Wlodarczyk M, Alkhrait S, Maajid E, Yang Q Drugs. 2023; 83(18):1649-1675.

PMID: 37922098 DOI: 10.1007/s40265-023-01958-6.

References
1.
Al-Hendy A, Lukes A, Poindexter 3rd A, Venturella R, Villarroel C, Critchley H . Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy. N Engl J Med. 2021; 384(7):630-642. PMC: 8262231. DOI: 10.1056/NEJMoa2008283. View

2.
Biro R, Richter R, Ortiz M, Sehouli J, David M . Effects of epigallocatechin gallate-enriched green tea extract capsules in uterine myomas: results of an observational study. Arch Gynecol Obstet. 2021; 303(5):1235-1243. DOI: 10.1007/s00404-020-05907-6. View

3.
Zota A, Geller R, VanNoy B, Marfori C, Tabbara S, Hu L . Phthalate Exposures and MicroRNA Expression in Uterine Fibroids: The FORGE Study. Epigenet Insights. 2020; 13:2516865720904057. PMC: 7031793. DOI: 10.1177/2516865720904057. View

4.
Fowler T, Garr D, Mager N, Stanley J . Enhancing primary care and preventive services through Interprofessional practice and education. Isr J Health Policy Res. 2020; 9(1):12. PMC: 7092466. DOI: 10.1186/s13584-020-00371-8. View

5.
Ichikawa S, Motosugi U, Omori M, Sano K, Omiya Y, Hirata S . MR-guided Focused Ultrasound for Uterine Fibroids: A Preliminary Study of Relationship between the Treatment Outcomes and Factors of MR Images Including Elastography. Magn Reson Med Sci. 2018; 18(1):82-87. PMC: 6326767. DOI: 10.2463/mrms.tn.2017-0103. View